GT BIOPHARMA, INC. (GTBP) Debt Components
- 2021-12-31: Secured Debt, CurrentUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD $31.00K; Convertible Notes PayableUSD (m).
- 2021-09-30: Secured Debt, CurrentUSD (m); Convertible Notes Payable, CurrentUSD $0.00; Long-term Line of CreditUSD $31.00K; Convertible Notes PayableUSD $38.80M.
- 2021-06-30: Secured Debt, CurrentUSD (m); Convertible Notes Payable, CurrentUSD $0.00; Long-term Line of CreditUSD $31.00K; Convertible Notes PayableUSD $38.80M.
- 2021-03-31: Secured Debt, CurrentUSD (m); Convertible Notes Payable, CurrentUSD $0.00; Long-term Line of CreditUSD $31.00K; Convertible Notes PayableUSD (m).
GT BIOPHARMA, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Secured Debt, Current USD | Convertible Notes Payable, Current USD | Long-term Line of Credit USD | Convertible Notes Payable USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Remaining Borrowing Capacity USD | Debt Instrument, Face Amount USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Unamortized Discount, Current USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Debt Instrument, Unamortized Discount USD | Notes Payable, Related Parties, Current USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $500.00K |
| 2021-09-30 | (m) | $0.00 | $31.00K | $38.80M | (m) | (m) | $33.27M | (m) | 3.40 | (m) | (m) | $0.00 | $525.00K |
| 2021-06-30 | (m) | $0.00 | $31.00K | $38.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $525.00K |
| 2021-03-31 | (m) | $0.00 | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) |
| 2021-02-16 | (m) | (m) | (m) | $38.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $2.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $30.82M | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.52M | $4.52M | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $4.75M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.52M | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.10M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $2.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $13.30M | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | $91.00K | (m) | $91.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.30M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-09-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-06-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-03-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2018-12-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00K |
| 2018-09-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | $488.00 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | $905.00K | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | $4.83M | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.83M | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) |
| 2017-09-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2017-06-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $215.00K | (m) |
| 2017-03-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $708.00K | (m) |
| 2016-12-31 | $889.00K | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | $794.00K | $2.54M | $794.00K | (m) |
| 2016-09-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.60M | (m) |
| 2016-06-30 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.95M | (m) |
| 2016-03-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.68M | (m) |
| 2015-12-31 | (m) | (m) | $31.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2015-09-30 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $593.00K | (m) |
| 2015-06-30 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $35.00K | (m) |
| 2015-03-31 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $38.00K | (m) |
| 2014-12-31 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2014-09-30 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2014-06-30 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $142.00K | (m) |
| 2013-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $244.00K | (m) |
| 2013-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $347.00K | (m) |
| 2013-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $515.00K | (m) |
| 2012-12-31 | (m) | (m) | $27.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $54.00K | (m) |
| 2012-09-30 | (m) | (m) | $26.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $26.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $25.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $25.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-11-08 | (m) | (m) | (m) | (m) | $300.00K | $800.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |